Journal: The FASEB Journal

Article Title: c‐Abl Kinase Targets Tight Junction Protein ZO ‐2 in Regulation of Cell Migration and Morphology

doi: 10.1096/fj.202402159R

Figure Lengend Snippet: Reduced traction by active c‐Abl acting on ZO‐2 and cytoskeletal changes within c‐Abl‐induced cells. (A) Schematic representation of traction and tension within a group of cells. Black arrows indicate traction exerted on the substrate, and gray arrows represent tension across the cell monolayer. (B) Image of a representative cell monolayer with yellow shading indicating region used for analyzing traction and stress. (C, D) Traction and stress for the KA and KA‐ZO2‐KO cells with and without Tet. Dots indicate the root‐mean‐square traction and mean stress values for each monolayer; horizontal lines indicate means across all experiments in each group. In panel C, for KA cells, Tet− and Tet+ are statistically different ( p = 0.0017, one‐way ANOVA with Tukey). In panel D, there are no statistical differences ( p = 0.13, one‐way ANOVA). (E) Immunofluorescence image of KA cells with and without tetracycline. Paxillin (red), actin (green), and nucleus (blue) were stained. Scale bar = 20 μm. (F) Quantification of paxillin signal intensity in KA and KA + Tet cells ( n = 20). (G) Quantification of actin stress fiber thickness in KA and KA + Tet cells ( n = 10). Signification is indicated as ** p < 0.01, *** p < 0.001.

Article Snippet: Antibodies used in Western blot analysis were c‐Abl monoclonal antibody (K2, Santa Cruz), flag monoclonal antibody (Sigma‐Aldrich, Cat. no. F3165, RRID: AB_259529), ZO‐2 polyclonal antibody (Santa Cruz, sc‐11448 [H‐110], RRID: AB_2203583), phospho‐tyrosine monoclonal antibody (4G10, Cell Signaling Technology, Cat. no. 96215, RRID: AB_3096295), β‐actin monoclonal antibody (Sigma‐Aldrich, Cat. no. A5441, RRID: AB_476744), Jak1 polyclonal antibody (Cell Signaling Technology, Cat. no. 3332, RRID: AB_2128499), and phospho‐Jak1 (Tyr1022/1023) polyclonal antibody (Cell Signaling Technology, Cat. no. 3331, RRID: AB_2265057).

Techniques: Immunofluorescence, Staining

Journal: International Journal of Molecular Medicine

Article Title: Angiopoietin-1 reduces vascular endothelial growth factor-induced brain endothelial permeability via upregulation of ZO-2

doi: 10.3892/ijmm_00000128

Figure Lengend Snippet: Figure 3. siRNA against ZO-2 abolished the anti-permeability effect of rAng-1 on rVEGF treated HBMECs. (A) HBMECs were transfected with siRNA targeting ZO-2 (siZO-2) and control nonsilencing siRNA (siCon), incubated for 24 h, then treated with 50 ng/ml rVEGF and 100 ng/ml rAng-1 for 3 h. ZO-2 protein and mRNA were analyzed (n=3). (B) RITC-dextran passage was analyzed for endothelial permeability in HBMECs under the same conditions as in A. Independent experiments were repeated two times.

Article Snippet: ZO-2 siRNA and the control nonsilencing siRNA were purchased from Santa Cruz.

Techniques: Permeability, Transfection, Control, Incubation

Journal: Cell reports

Article Title: p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP

doi: 10.1016/j.celrep.2023.113486

Figure Lengend Snippet:

Article Snippet: ZO-2 , Boster , Cat# PA1957.

Techniques:

Journal: Cell reports

Article Title: p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP

doi: 10.1016/j.celrep.2023.113486

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: ZO-2 , Boster , Cat# PA1957.

Techniques: Virus, Recombinant, cDNA Synthesis, RNA Sequencing, Knockdown, Plasmid Preparation, shRNA, Software